These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 24338723

  • 1. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
    Wu RC, Ayhan A, Maeda D, Kim KR, Clarke BA, Shaw P, Chui MH, Rosen B, Shih IeM, Wang TL.
    J Pathol; 2014 Mar; 232(4):473-81. PubMed ID: 24338723
    [Abstract] [Full Text] [Related]

  • 2. Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation.
    Huang HN, Chiang YC, Cheng WF, Chen CA, Lin MC, Kuo KT.
    Mod Pathol; 2015 Feb; 28(2):303-11. PubMed ID: 25081752
    [Abstract] [Full Text] [Related]

  • 3. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
    Ayhan A, Kuhn E, Wu RC, Ogawa H, Bahadirli-Talbott A, Mao TL, Sugimura H, Shih IM, Wang TL.
    Mod Pathol; 2017 Feb; 30(2):297-303. PubMed ID: 27767100
    [Abstract] [Full Text] [Related]

  • 4. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
    Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O.
    Virchows Arch; 2012 Jan; 460(1):77-87. PubMed ID: 22120431
    [Abstract] [Full Text] [Related]

  • 5. Uncommon Human Telomerase Reverse Transcriptase Promoter Mutations Are Associated With Poor Survival in Ovarian Clear Cell Carcinoma.
    Nishikimi K, Nakagawa K, Tate S, Matsuoka A, Iwamoto M, Kiyokawa T, Shozu M.
    Am J Clin Pathol; 2018 Mar 07; 149(4):352-361. PubMed ID: 29474637
    [Abstract] [Full Text] [Related]

  • 6. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.
    Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O.
    Mod Pathol; 2012 Apr 07; 25(4):615-24. PubMed ID: 22157930
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
    Huang HN, Lin MC, Huang WC, Chiang YC, Kuo KT.
    Mod Pathol; 2014 Jul 07; 27(7):983-90. PubMed ID: 24336158
    [Abstract] [Full Text] [Related]

  • 10. ARID1A mutations in endometriosis-associated ovarian carcinomas.
    Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih IeM, Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG.
    N Engl J Med; 2010 Oct 14; 363(16):1532-43. PubMed ID: 20942669
    [Abstract] [Full Text] [Related]

  • 11. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
    Rahman M, Nakayama K, Rahman MT, Nakayama N, Ishikawa M, Katagiri A, Iida K, Nakayama S, Otsuki Y, Shih IeM, Miyazaki K.
    Hum Pathol; 2012 Dec 14; 43(12):2197-206. PubMed ID: 22705003
    [Abstract] [Full Text] [Related]

  • 12. TERT promoter mutation in adult granulosa cell tumor of the ovary.
    Pilsworth JA, Cochrane DR, Xia Z, Aubert G, Färkkilä AEM, Horlings HM, Yanagida S, Yang W, Lim JLP, Wang YK, Bashashati A, Keul J, Wong A, Norris K, Brucker SY, Taran FA, Krämer B, Staebler A, van Meurs H, Oliva E, Shah SP, Kommoss S, Kommoss F, Gilks CB, Baird DM, Huntsman DG.
    Mod Pathol; 2018 Jul 14; 31(7):1107-1115. PubMed ID: 29449679
    [Abstract] [Full Text] [Related]

  • 13. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
    Cevik D, Yildiz G, Ozturk M.
    World J Gastroenterol; 2015 Jan 07; 21(1):311-7. PubMed ID: 25574106
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup.
    Pirker C, Bilecz A, Grusch M, Mohr T, Heidenreich B, Laszlo V, Stockhammer P, Lötsch-Gojo D, Gojo J, Gabler L, Spiegl-Kreinecker S, Dome B, Steindl A, Klikovits T, Hoda MA, Jakopovic M, Samarzija M, Mohorcic K, Kern I, Kiesel B, Brcic L, Oberndorfer F, Müllauer L, Klepetko W, Schmidt WM, Kumar R, Hegedus B, Berger W.
    Clin Cancer Res; 2020 Jul 15; 26(14):3819-3830. PubMed ID: 32317288
    [Abstract] [Full Text] [Related]

  • 18. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
    Liu T, Wang N, Cao J, Sofiadis A, Dinets A, Zedenius J, Larsson C, Xu D.
    Oncogene; 2014 Oct 16; 33(42):4978-84. PubMed ID: 24141777
    [Abstract] [Full Text] [Related]

  • 19. Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.
    Ye S, Zhou S, Wu Y, Pei X, Jiang W, Shi W, Yang W, Zhou X, Shan B, Yang H.
    Ann Med; 2023 Dec 16; 55(1):2218104. PubMed ID: 37272300
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.